ECONOMIC EVALUATION OF PCV20 IN PEDIATRIC POPULATION TO PREVENT PNEUMOCOCCAL INFECTIONS IN GUATEMALA: A HEALTHCARE PERSPECTIVE ANALYSIS
Author(s)
Andreina Jose Alamo, BSc1, Jair A. Arciniegas, MSc2, Jaime Ordoñez, MEd, PhD3, Jorge LaRotta, MD4, Juan Manuel Reyes, MSc5.
1PFIZER COLOMBIA, Bogota, Colombia, 2Value & Evidence Coordinator, Pfizer SAS, Bogotá, Colombia, 3TrueConsulting, MEDELLIN, Colombia, 4Pfizer, Bogotá, Colombia, 5Pfizer SAS, Bogotá, Colombia.
1PFIZER COLOMBIA, Bogota, Colombia, 2Value & Evidence Coordinator, Pfizer SAS, Bogotá, Colombia, 3TrueConsulting, MEDELLIN, Colombia, 4Pfizer, Bogotá, Colombia, 5Pfizer SAS, Bogotá, Colombia.
OBJECTIVES: To evaluate the cost-utility of updating the pneumococcal vaccination schedule with PCV20 in the pediatric population from the Guatemalan healthcare system perspective.
METHODS: A multicohort Markov decision model was utilized to assess PCV20 against PCV13 (the current standard of care) for pneumococcal disease prevention in children under 1 year old. The technologies studied are the available conjugated technologies at the PAHO revolving fund. Under a ten-year time horizon, ten annual newborns cohort were analyzed. Quality-adjusted life years [QALY] were the main clinical outcome, and direct medical costs were estimated, both discounted at 5% from the Guatemalan healthcare perspective. Vaccine uptake was assumed to be 86.7%, based on historical vaccination coverage. Epidemiological and effectiveness parameters were obtained from published literature and national records. Cost inputs were sourced from local repositories, PAHO and were reported in USD dollars.
RESULTS: PCV20 led to avert 671 IPD cases, 7,784 non-invasive hospitalized pneumonia cases, 12,039 outpatient pneumonia cases, 6,546 otitis media cases and 48 deaths. These epidemiological benefits translated into 7,275 additional QALYs. Direct medical costs were USD 612.7 million with PCV13 and USD 589.2 million with PCV20. Sequelae-related costs were USD 18.4 million and USD 11.1 million, respectively. PCV13 vaccination costs were 103.6 million and 150 million with PCV20. These findings indicate that PCV20 represents a cost-effective alternative, considering the incremental cost-effectiveness ratio was 2,159 USD per QALY compared with PCV13, as it locates under the 1xGDP per capita cost-effectiveness threshold in Guatemala (6,820 USD).
CONCLUSIONS: PCV20 is expected to reduce the burden of pneumococcal disease substantially, prevent deaths, and improve population health outcomes in Guatemala. Given its favorable cost-effectiveness profile, PCV20 represents an efficient use of healthcare resources and should be considered as an alternative to the current pediatric pneumococcal vaccination strategy.
METHODS: A multicohort Markov decision model was utilized to assess PCV20 against PCV13 (the current standard of care) for pneumococcal disease prevention in children under 1 year old. The technologies studied are the available conjugated technologies at the PAHO revolving fund. Under a ten-year time horizon, ten annual newborns cohort were analyzed. Quality-adjusted life years [QALY] were the main clinical outcome, and direct medical costs were estimated, both discounted at 5% from the Guatemalan healthcare perspective. Vaccine uptake was assumed to be 86.7%, based on historical vaccination coverage. Epidemiological and effectiveness parameters were obtained from published literature and national records. Cost inputs were sourced from local repositories, PAHO and were reported in USD dollars.
RESULTS: PCV20 led to avert 671 IPD cases, 7,784 non-invasive hospitalized pneumonia cases, 12,039 outpatient pneumonia cases, 6,546 otitis media cases and 48 deaths. These epidemiological benefits translated into 7,275 additional QALYs. Direct medical costs were USD 612.7 million with PCV13 and USD 589.2 million with PCV20. Sequelae-related costs were USD 18.4 million and USD 11.1 million, respectively. PCV13 vaccination costs were 103.6 million and 150 million with PCV20. These findings indicate that PCV20 represents a cost-effective alternative, considering the incremental cost-effectiveness ratio was 2,159 USD per QALY compared with PCV13, as it locates under the 1xGDP per capita cost-effectiveness threshold in Guatemala (6,820 USD).
CONCLUSIONS: PCV20 is expected to reduce the burden of pneumococcal disease substantially, prevent deaths, and improve population health outcomes in Guatemala. Given its favorable cost-effectiveness profile, PCV20 represents an efficient use of healthcare resources and should be considered as an alternative to the current pediatric pneumococcal vaccination strategy.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE288
Topic
Economic Evaluation
Disease
Vaccines